Stem cell therapy ranges from genuinely safe, well-established medical treatments to dangerous, unregulated procedures sold by clinics with no oversight. The safety depends almost entirely on what type of stem cell therapy you’re considering, where you’re getting it, and what condition it’s meant to treat. Only a small number of stem cell products are FDA-approved, and the vast majority of treatments marketed directly to consumers have never been evaluated for safety or effectiveness.
What’s Actually FDA-Approved
The FDA has approved roughly a dozen stem cell-based products, and most of them are cord blood products used for blood disorders and certain cancers. These include products like Hemacord, Allocord, and Ducord, which supply blood-forming stem cells for transplantation. One newer product, Omisirge, is an expanded cord blood therapy. Ryoncil is approved for a specific complication of bone marrow transplants in children. That’s essentially the full list.
If a clinic is offering stem cell injections for joint pain, anti-aging, neurological conditions, lung disease, or erectile dysfunction, those treatments are not FDA-approved. The FDA has been explicit: patients should avoid stem cell products used outside of controlled clinical trials unless the product is specifically approved for that use. The agency continues to receive reports of serious harm and even patient deaths from unapproved products, including a recent case involving an imported placental tissue product called Laennec.
Safety of Approved Stem Cell Transplants
For established stem cell transplants used in cancer treatment and blood disorders, the risks are real but well-understood and managed in clinical settings. The safety profile depends heavily on whether the cells come from your own body or a donor.
With autologous transplants, where your own stem cells are collected and returned to you, there’s no risk of your body rejecting the cells and no risk of graft-versus-host disease, a condition where donor immune cells attack your healthy tissue. The main risks are that the transplant might not “take,” meaning the stem cells don’t settle into the bone marrow and start producing blood cells, or that cancer cells could survive the collection process and get reintroduced.
Allogeneic transplants use cells from a donor, and they carry more risk. Graft-versus-host disease is the most significant concern. In this condition, the donor’s immune cells treat your body as foreign and attack your organs, skin, or digestive system. It can range from mild to life-threatening, though prevention and treatment have improved considerably in recent years. Donor transplants also carry a small risk of infections transmitted through the donated cells, and old infections you had before the transplant can reactivate. On the positive side, donor cells can produce a graft-versus-cancer effect, where the new immune system helps destroy remaining cancer cells.
Side Effects in Clinical Trials
A systematic review of cell therapy trials for chronic spinal cord injury found 64 different types of adverse events across 45 studies. The most common were temporary back pain and symptoms resembling meningitis irritation, reported in up to 90% of participants in some studies. A meta-analysis put the overall prevalence of adverse events at 19%, with urinary tract issues and problems at the injection site being the most frequent. Importantly, none of the adverse events in these trials reached the severity of life-threatening consequences or death.
That’s a meaningful finding, but it comes with a critical caveat: these were controlled clinical trials with careful patient screening, sterile manufacturing, and close monitoring. The safety profile of the same types of cells administered in an unregulated clinic, without those protections, is a completely different story.
The Danger of Unregulated Clinics
Hundreds of clinics across the United States market stem cell treatments for conditions ranging from arthritis to autism, often charging thousands of dollars per session. A Pew Charitable Trusts investigation documented serious, life-altering harms from these unapproved treatments: 9 cases of partial or complete blindness, 16 cases of tumors or abnormal growths, 6 pulmonary embolisms, 5 cardiac arrests, and at least one case of paraplegia. In one particularly devastating case, patients who received stem cell eye injections developed hemorrhaging and retinal detachment, leaving them completely blind in both eyes or with minimal remaining vision a year later.
Contamination is another serious risk. In 2018, at least 13 people were hospitalized with severe bacterial infections after receiving contaminated cord blood products distributed to clinics in Texas, Arizona, Kansas, and Florida. When the CDC tested unopened vials from these clinics, they found multiple species of bacteria growing in the products. Cord blood cannot be sterilized after collection without destroying the cells, so manufacturing must be tightly controlled. The product in question was not FDA-approved, and the companies involved were merely registered with the FDA, which is not a form of approval and does not demonstrate compliance with safety standards.
Red Flags to Watch For
The International Society for Stem Cell Research, the leading professional organization in the field, has outlined specific warning signs that a stem cell offering is not legitimate:
- Claims of cures. Language suggesting a treatment is “curative” should not be used without evidence of complete or permanent relief. Clinics that promise to cure chronic diseases with stem cells are making claims no current evidence supports.
- Patient testimonials as proof. Anecdotes and testimonials are not substitutes for clinical trial data. Clinics that rely on patient stories rather than published research are using a marketing tactic, not presenting evidence.
- Pay-to-participate research. Legitimate clinical trials do not charge patients for experimental treatments. If a clinic asks you to pay to join a “study,” that raises serious concerns about whether it’s genuine research or a business model built on selling unproven treatments.
- One treatment for many conditions. A single stem cell product marketed for joint pain, neurological disease, lung conditions, and cosmetic purposes is a red flag. Legitimate therapies are developed and tested for specific conditions.
Even a listing on a clinical trial database like ClinicalTrials.gov does not guarantee a trial has been vetted by regulators or meets safety guidelines. Always verify that a trial is conducted under an FDA investigational new drug application.
Who Should Not Get Stem Cell Therapy
Even in legitimate clinical settings, not everyone is a candidate. A history of cancer is a well-established exclusion criterion for many types of stem cell therapy, because stem cells can have unpredictable effects on tumor growth and behavior. Patients are typically screened thoroughly for hidden malignancies before treatment begins.
People at elevated risk for blood clots also face higher danger, as some stem cell products can trigger thromboembolism. Donors are screened for infectious diseases, and patients need to be evaluated for any condition that would make standard anti-inflammatory or antihistamine pre-treatment unsafe. The effectiveness and safety of cell therapy are shaped significantly by the individual patient’s medical history, which is why comprehensive screening matters so much and why off-the-shelf treatments from unregulated clinics are so risky.
What Monitoring Looks Like After Treatment
After a legitimate stem cell transplant, monitoring is extensive and ongoing. Clinicians track immune system recovery through regular blood draws, checking how well new immune cells are developing and watching for signs of complications like graft-versus-host disease or infection. Newer techniques allow doctors to detect residual disease and track genetic changes through simple blood samples rather than more invasive procedures.
This kind of follow-up is part of what makes approved stem cell therapy manageable. The risks are real, but they’re anticipated, monitored, and treated early when they arise. That infrastructure simply doesn’t exist at clinics offering same-day stem cell injections with no follow-up plan, which is one of the core reasons those treatments carry so much more risk than they advertise.